Trial Profile

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inaticabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
Indications Diffuse large B cell lymphoma; Follicular lymphoma
Focus Adverse reactions
Sponsors Juventas Cell Therapy

Most Recent Events

24 Mar 2023 Status changed from active, no longer recruiting to completed.
09 Feb 2021 Status changed from recruiting to active, no longer recruiting.
10 Aug 2020 According to a CASI Pharmaceuticals media release, the company expects to complete this study in first quarter.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com